Megakaryocytopoiesis in Stem Cell Transplantation.
Annual rept. 16 Sep 94-15 Sep 95,
NORTHWESTERN UNIV EVANSTON IL
Pagination or Media Count:
Following high-dose chemotherapy for the treatment of malignant disease, reinfusion of peripheral blood stem cells collected during treatment with growth factors usually results in delayed platelet engrafiment as compared to neutrophil recovery. The overall objective of this research proposal is to improve the capacity of stem cells to engrafi the megakaryocytic lineage. To achieve this goal we carried out ex vivo expansion of megakaryocyte Mk progenitors from human bone marrow BM and peripheral blood stem cells PBSO. Thanks to the availability of the recently cloned thrombopoietin TPO, a growth factor specific for the MK lineage, we obtained highly enriched MK cultures in both hematopoietic sources. A synergistic effect between TPO and low doses of interleukin-3 lL-3, but not stem cell factor SOF, was observed in bone marrow cultures. Neither lL-3 nor SOF, at the concentrations used, enhanced TPO-stimulated megakaryocytopoiesis in PBSC. These observations will be used for ex vivo expansion of MKs to treat post-transplant-associated thrombocytopenia.
- Anatomy and Physiology
- Medicine and Medical Research